Sodium Glucose Cotransporter-2 Inhibitors in Clinical Practice: Impact beyond Glycemic Control

Abstract

See, stats, and : https : / / www . researchgate . net / publication / 306129153 Sodium -2 Clinical : Impact Control Article DOI : 10. 5005 / jp - journals - 10043 - 0035 CITATIONS 0 READS 40 2 , including : Some : " Inflammatory - markers – can - an observational " View Prasanna Center 84 SEE All . The . All - text and , letting . ABSTRACT Type 2 diabetes mellitus is a metabolic disorder that occurs due to an interplay of multiple perplexing pathophysiological mechanisms and leads to hyperglycemia . However , till date there has been no single unique molecule that can by itself effectively address all the metabolic abnormalities occurring in type 2 diabetes . Furthermore , type 2 diabetes must be managed with agents that can combat hyperglycemia without causing hypoglycemia and adverse cardiovascular outcomes . Thus , the need of the hour is for a unique molecule that can deliver beyond glycemic control and can in addition address the cardiovascular risk factors that arise in type 2 diabetes . Sodium glucose cotransporter - 2 (SGLT - 2) inhibitors are the latest of the oral hypoglycemic agents that act by insulin - independent mechanisms and tackle several cardiovascular risk factors that occur in type 2 diabetes . The scope of this article will be to focus primarily on the cardiovascular benefits of SGLT - 2 inhibitors and its actions beyond glycemic control in providing a comprehensive care in the management of type 2 diabetes .